Prophylactic strategies before solid-organ transplantation

Research output: Contribution to journalArticle

Abstract

Purpose of review: Prophylactic measures prior to organ transplantation are evolving based on recent reports of emerging infectious diseases, as well as an expanded understanding of the epidemiology of familiar infections. This review will highlight developments with potential impact on donor and recipient screening and pretransplant management. Recent findings: Key findings regarding bacterial infections include the lack of utility of mupirocin intranasal decolonization for prevention of Staphylococcus aureus infections after liver transplantation, and the description of transmission of Pseudomonas infection to multiple recipients via an innominate artery graft. The implications of donor bacterial colonization in lung transplantation are further explored. The emergence of non-Candida albicans yeast and non-Aspergillus mold infections may lead to changes in prophylactic strategies. The majority of cystic fibrosis patients have had Aspergillus colonization at some time before transplant; one-quarter of these develop tracheobronchial aspergillosis and anastomotic complications. There are several key developments regarding viral infections. Donor-derived human herpesvirus-8-infected neoplastic cells have been identified in recipients with Kaposi sarcoma. The transmission of human T-cell lymphotropic virus -1 (HTLV-1) to multiple recipients who developed myelopathy underscores the continuing need for donor screening. The striking event of West Nile virus transmission to multiple recipients from a single donor also has raised questions regarding donor screening for this virus. New information on the use of hepatitis B core antibody-positive donor livers, as well as the emergence of hepatitis B virus escape mutants, is discussed. Finally, information on successful retransplantation after BK polyomavirus (BKV) allograft nephropathy is beginning to appear. Summary: The pretransplant phase continues to be an important time period for screening and intervention in order to reduce the risk of posttransplant infections. Recent findings add to our current understanding of epidemiology and risk stratification; however, more randomized trials are needed.

Original languageEnglish (US)
Pages (from-to)353-356
Number of pages4
JournalCurrent Opinion in Infectious Diseases
Volume17
Issue number4
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Organ Transplantation
Donor Selection
Tissue Donors
Infection
Epidemiology
Mupirocin
Emerging Communicable Diseases
BK Virus
Brachiocephalic Trunk
Transplants
Hepatitis B Antibodies
Pseudomonas Infections
Human Herpesvirus 8
West Nile virus
Human T-lymphotropic virus 1
Aspergillosis
Lung Transplantation
Spinal Cord Diseases
Kaposi's Sarcoma
Virus Diseases

Keywords

  • Donor
  • Prophylaxis
  • Recipient
  • Screening
  • Transplantation

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology

Cite this

Prophylactic strategies before solid-organ transplantation. / Avery, Robin.

In: Current Opinion in Infectious Diseases, Vol. 17, No. 4, 08.2004, p. 353-356.

Research output: Contribution to journalArticle

@article{8885385ac7bb4c1e848c764d68b34a29,
title = "Prophylactic strategies before solid-organ transplantation",
abstract = "Purpose of review: Prophylactic measures prior to organ transplantation are evolving based on recent reports of emerging infectious diseases, as well as an expanded understanding of the epidemiology of familiar infections. This review will highlight developments with potential impact on donor and recipient screening and pretransplant management. Recent findings: Key findings regarding bacterial infections include the lack of utility of mupirocin intranasal decolonization for prevention of Staphylococcus aureus infections after liver transplantation, and the description of transmission of Pseudomonas infection to multiple recipients via an innominate artery graft. The implications of donor bacterial colonization in lung transplantation are further explored. The emergence of non-Candida albicans yeast and non-Aspergillus mold infections may lead to changes in prophylactic strategies. The majority of cystic fibrosis patients have had Aspergillus colonization at some time before transplant; one-quarter of these develop tracheobronchial aspergillosis and anastomotic complications. There are several key developments regarding viral infections. Donor-derived human herpesvirus-8-infected neoplastic cells have been identified in recipients with Kaposi sarcoma. The transmission of human T-cell lymphotropic virus -1 (HTLV-1) to multiple recipients who developed myelopathy underscores the continuing need for donor screening. The striking event of West Nile virus transmission to multiple recipients from a single donor also has raised questions regarding donor screening for this virus. New information on the use of hepatitis B core antibody-positive donor livers, as well as the emergence of hepatitis B virus escape mutants, is discussed. Finally, information on successful retransplantation after BK polyomavirus (BKV) allograft nephropathy is beginning to appear. Summary: The pretransplant phase continues to be an important time period for screening and intervention in order to reduce the risk of posttransplant infections. Recent findings add to our current understanding of epidemiology and risk stratification; however, more randomized trials are needed.",
keywords = "Donor, Prophylaxis, Recipient, Screening, Transplantation",
author = "Robin Avery",
year = "2004",
month = "8",
doi = "10.1097/01.qco.0000136936.13662.74",
language = "English (US)",
volume = "17",
pages = "353--356",
journal = "Current Opinion in Infectious Diseases",
issn = "0951-7375",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Prophylactic strategies before solid-organ transplantation

AU - Avery, Robin

PY - 2004/8

Y1 - 2004/8

N2 - Purpose of review: Prophylactic measures prior to organ transplantation are evolving based on recent reports of emerging infectious diseases, as well as an expanded understanding of the epidemiology of familiar infections. This review will highlight developments with potential impact on donor and recipient screening and pretransplant management. Recent findings: Key findings regarding bacterial infections include the lack of utility of mupirocin intranasal decolonization for prevention of Staphylococcus aureus infections after liver transplantation, and the description of transmission of Pseudomonas infection to multiple recipients via an innominate artery graft. The implications of donor bacterial colonization in lung transplantation are further explored. The emergence of non-Candida albicans yeast and non-Aspergillus mold infections may lead to changes in prophylactic strategies. The majority of cystic fibrosis patients have had Aspergillus colonization at some time before transplant; one-quarter of these develop tracheobronchial aspergillosis and anastomotic complications. There are several key developments regarding viral infections. Donor-derived human herpesvirus-8-infected neoplastic cells have been identified in recipients with Kaposi sarcoma. The transmission of human T-cell lymphotropic virus -1 (HTLV-1) to multiple recipients who developed myelopathy underscores the continuing need for donor screening. The striking event of West Nile virus transmission to multiple recipients from a single donor also has raised questions regarding donor screening for this virus. New information on the use of hepatitis B core antibody-positive donor livers, as well as the emergence of hepatitis B virus escape mutants, is discussed. Finally, information on successful retransplantation after BK polyomavirus (BKV) allograft nephropathy is beginning to appear. Summary: The pretransplant phase continues to be an important time period for screening and intervention in order to reduce the risk of posttransplant infections. Recent findings add to our current understanding of epidemiology and risk stratification; however, more randomized trials are needed.

AB - Purpose of review: Prophylactic measures prior to organ transplantation are evolving based on recent reports of emerging infectious diseases, as well as an expanded understanding of the epidemiology of familiar infections. This review will highlight developments with potential impact on donor and recipient screening and pretransplant management. Recent findings: Key findings regarding bacterial infections include the lack of utility of mupirocin intranasal decolonization for prevention of Staphylococcus aureus infections after liver transplantation, and the description of transmission of Pseudomonas infection to multiple recipients via an innominate artery graft. The implications of donor bacterial colonization in lung transplantation are further explored. The emergence of non-Candida albicans yeast and non-Aspergillus mold infections may lead to changes in prophylactic strategies. The majority of cystic fibrosis patients have had Aspergillus colonization at some time before transplant; one-quarter of these develop tracheobronchial aspergillosis and anastomotic complications. There are several key developments regarding viral infections. Donor-derived human herpesvirus-8-infected neoplastic cells have been identified in recipients with Kaposi sarcoma. The transmission of human T-cell lymphotropic virus -1 (HTLV-1) to multiple recipients who developed myelopathy underscores the continuing need for donor screening. The striking event of West Nile virus transmission to multiple recipients from a single donor also has raised questions regarding donor screening for this virus. New information on the use of hepatitis B core antibody-positive donor livers, as well as the emergence of hepatitis B virus escape mutants, is discussed. Finally, information on successful retransplantation after BK polyomavirus (BKV) allograft nephropathy is beginning to appear. Summary: The pretransplant phase continues to be an important time period for screening and intervention in order to reduce the risk of posttransplant infections. Recent findings add to our current understanding of epidemiology and risk stratification; however, more randomized trials are needed.

KW - Donor

KW - Prophylaxis

KW - Recipient

KW - Screening

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=3843123129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3843123129&partnerID=8YFLogxK

U2 - 10.1097/01.qco.0000136936.13662.74

DO - 10.1097/01.qco.0000136936.13662.74

M3 - Article

C2 - 15241081

AN - SCOPUS:3843123129

VL - 17

SP - 353

EP - 356

JO - Current Opinion in Infectious Diseases

JF - Current Opinion in Infectious Diseases

SN - 0951-7375

IS - 4

ER -